/ELDN

ELDN Stock - Eledon Pharmaceuticals, Inc.

Q: What is the analyst price target for ELDN?

Analyst price target information is not currently available for ELDN.

Q: What is ELDN's market cap?

Market capitalization information is not currently available for ELDN.

Healthcare|Biotechnology|NASDAQ

$1.64+4.46%

+$0.07 (+4.46%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+448.8%upside

Target: $9.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ELDN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.80

52W High$4.98

52W Low$1.35

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-359,000	$-374,000	$-373,000	$-195,000	$-183,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-70,577,000	$-43,000,000	$-39,780,000	$-36,867,000	$-13,283,000
Net Income	$-36,184,000	$-116,537,000	$-87,966,000	$-34,506,000	$-22,811,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.75	$-0.00	$-6.13	$-2.33	$-15.72

Company Overview

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

$11

Average Target

↑ 570.7% Upside

Now

Low

$11

Average

$15

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
June 18th 2025	H.C. Wainwright	Resumed	Buy	$9
January 28th 2025	Guggenheim	Initiation	Buy	$9
May 13th 2022	Cantor Fitzgerald	Resumed	Overweight	$15← $25

Earnings History & Surprises

ELDN

Beat Rate

67%

Last 18 quarters

Avg Surprise

+6.2%

EPS vs Estimate

Beats / Misses

12/6

Last 12 quarters

Latest EPS

$-0.21

Q4 2025

EPS Surprise History

Q1 24

+23.7%

$-0.29vs$-0.38

Q2 24

+8.1%

$-0.34vs$-0.37

Q3 24

-3.2%

$-0.32vs$-0.31

Q4 24

-6.7%

$-0.32vs$-0.30

Q1 25

-100.0%

$-0.64vs$-0.32

Q2 25

+71.4%

$-0.08vs$-0.28

Q3 25

+43.5%

$-0.13vs$-0.23

Q4 25

+4.5%

$-0.21vs$-0.22

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 12, 2026	—	—	—	—
Q1 2026	Mar 19, 2026	$-0.20	—	—	—
Q4 2025	Nov 14, 2025	$-0.22	$-0.21	+4.5%	✓ BEAT
Q3 2025	Aug 14, 2025	$-0.23	$-0.13	+43.5%	✓ BEAT
Q2 2025	May 14, 2025	$-0.28	$-0.08	+71.4%	✓ BEAT
Q1 2025	Mar 20, 2025	$-0.32	$-0.64	-100.0%	✗ MISS
Q4 2024	Nov 12, 2024	$-0.30	$-0.32	-6.7%	✗ MISS
Q3 2024	Aug 19, 2024	$-0.31	$-0.32	-3.2%	✗ MISS
Q2 2024	May 9, 2024	$-0.37	$-0.34	+8.1%	✓ BEAT
Q1 2024	Mar 28, 2024	$-0.38	$-0.29	+23.7%	✓ BEAT
Q4 2023	Nov 9, 2023	$-0.41	$-0.35	+14.6%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.47	$-0.40	+14.9%	✓ BEAT
Q2 2023	May 11, 2023	$-0.71	$-0.75	-5.6%	✗ MISS
Q1 2023	Mar 30, 2023	$-0.70	$-0.68	+2.9%	✓ BEAT
Q4 2022	Nov 14, 2022	$-0.68	$-0.73	-7.4%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.72	$-0.65	+9.7%	✓ BEAT
Q2 2022	May 12, 2022	$-0.67	$-0.69	-3.0%	✗ MISS
Q1 2022	Mar 24, 2022	$-0.83	$-0.59	+28.9%	✓ BEAT
Q4 2021	Nov 11, 2021	$-0.67	$-0.66	+1.5%	✓ BEAT
Q3 2021	Aug 12, 2021	$-0.58	$-0.50	+13.8%	✓ BEAT

Frequently Asked Questions about ELDN

What is ELDN's current stock price?

Eledon Pharmaceuticals, Inc. (ELDN) is currently trading at $1.64 per share. The stock has moved +4.46% today.

What is the analyst price target for ELDN?

The average analyst price target for ELDN is $9.00, based on 1 analyst.

What sector is Eledon Pharmaceuticals, Inc. in?

Eledon Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is ELDN's market cap?

Eledon Pharmaceuticals, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.

Does ELDN pay dividends?

No, Eledon Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.